Pipeline

We are developing differentiated peptide candidates to address unmet medical needs across therapeutic areas.

 
PARTNERS
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
REGISTRATION
Obesity
PROGRAM Petrelintide
Phase 1
PROGRAM Dapiglutide
Phase 1
PROGRAM Survodutide
PARTNERS 300X180 Logo Boehringer
Phase 3
PROGRAM ZP6590
Preclinical
Congenital Hyperinsulinism
Short Bowel Syndrome
PROGRAM Glepaglutide
Registration
Chronic inflammation
PROGRAM ZP9830
Preclinical
PROGRAM ZP10068
Preclinical
Type 1 diabetes
PROGRAM Dasiglucagon: Diabetes
Phase 2

Latest scientific publications

All Scientific publications
  • EASL Congress

    Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis: Results from a randomized, double-blind, placebo-controlled phase 2 trial

  • Diabetes, Obesity and Metabolism

    The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection

  • The Lancet

    Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial

  • Diabetalogia

    Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial

We are targeting a number of important therapeutic areas of high unmet need with our robust pipeline of differentiated candidates.

David Kendall

Chief Medical Officer, Zealand Pharma

David ALR0987